NEU — Neuren Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$1.85bn
- AU$1.63bn
- AU$224.26m
- 65
- 63
- 31
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 52.13 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -51.54% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.09 | ||
| Price to Tang. Book | 5.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.25 | ||
| EV to EBITDA | 8.73 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 51.27% | ||
| Return on Equity | 49.92% | ||
| Operating Margin | 83.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.86 | 3.24 | 15.81 | 237.63 | 224.26 | 65.67 | 137.19 | 202.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +84569.86 | -12.14 | -88.68 | +240.65 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
Directors
- Patrick Davies NEC (54)
- Jon Pilcher CEO
- Lauren Frazer CFO
- Larry Glass CSO
- James Shaw VOP
- Joseph Horrigan VPR
- Gerry Zhao VBD
- Dianne Angus NID
- Jenny Harry NID
- Trevor Scott NID
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 2001
- Public Since
- February 3rd, 2005
- No. of Shareholders
- 11,593
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 127,012,624
- Address
- SE 201 697 Burke Rd, Camberwell, MELBOURNE, 3124
- Web
- https://www.neurenpharma.com/
- Phone
- +61 390920480
- Auditors
- Grant Thornton
Upcoming Events for NEU
Similar to NEU
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Neuren Pharmaceuticals share price?
As of Today at 22:15 UTC, shares in Neuren Pharmaceuticals are trading at AU$14.57. This share price information is delayed by 15 minutes.
How has the Neuren Pharmaceuticals share price performed this year?
Shares in Neuren Pharmaceuticals last closed at AU$14.57 and the price had moved by -26.64% over the past 365 days. In terms of relative price strength the Neuren Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -32.35% over the past year.
What are the analyst and broker recommendations for Neuren Pharmaceuticals?
The overall consensus recommendation for Neuren Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neuren Pharmaceuticals dividend yield?
Neuren Pharmaceuticals does not currently pay a dividend.
Does Neuren Pharmaceuticals pay a dividend?
Neuren Pharmaceuticals does not currently pay a dividend.
When does Neuren Pharmaceuticals next pay dividends?
Neuren Pharmaceuticals does not currently pay a dividend.
How do I buy Neuren Pharmaceuticals shares?
To buy shares in Neuren Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neuren Pharmaceuticals?
As of the previous close price of AU$14.57, shares in Neuren Pharmaceuticals had a market capitalisation of AU$1.85bn.
Where are Neuren Pharmaceuticals shares listed?
Here are the trading details for Neuren Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NEU
What kind of share is Neuren Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Neuren Pharmaceuticals is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neuren Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Neuren Pharmaceuticals is AU$24.88. That is 70.75% above the last closing price of AU$14.57.
Analysts covering Neuren Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of AU$0.12 for the next financial year.
Find out moreWhat is the trend in the Neuren Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuren Pharmaceuticals. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +16.95%.
As of the last closing price of AU$14.57, shares in Neuren Pharmaceuticals were trading +12.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neuren Pharmaceuticals PE Ratio?
The Neuren Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 52.13. The shares last closed at AU$14.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neuren Pharmaceuticals?
Neuren Pharmaceuticals' management team is headed by:
- Patrick Davies - NEC
- Jon Pilcher - CEO
- Lauren Frazer - CFO
- Larry Glass - CSO
- James Shaw - VOP
- Joseph Horrigan - VPR
- Gerry Zhao - VBD
- Dianne Angus - NID
- Jenny Harry - NID
- Trevor Scott - NID